William Blair initiated coverage of Ultragenyx (RARE) with an Outperform rating and $65 fair value estimate. Ultragenyx is a commercial-stage, modality-agnostic biotechnology company specializing in developing therapies for the treatment of rare and ultrarare genetic diseases, the analyst tells investors in a research note. The firm says that since 2017, the company has commercialized four products, which in aggregate generated $560M in revenue in 2024, up 29% year-over-year. It anticipates Ultragenyx’s legacy products will continue to provide a “strong revenue foundation” for the company through the early 2030s.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx Pharmaceutical Approves Key Proposals at Annual Meeting
- Optimistic Buy Rating for Ultragenyx: Strategic Developments and Favorable Regulatory Landscape Drive Growth Prospects
- Ultragenyx Pharmaceutical: Promising Growth and Strategic Milestones Reinforce Buy Rating
- Ultragenyx Reports Strong Growth Amid Challenges
- Ultragenyx price target lowered to $100 from $140 at Truist